President of Janssen Cardiovascular & Metabolism in the U.S. with strategic oversight for full Janssen Portfolio in Canada and Puerto Rico. Accountable for developing & delivering business strategy, including full P&L responsibility, sales, marketing & medical affairs, lifecycle management, external alliances, and collaboration with R&D. Board member for Janssen Pharmaceutical North America, one of the largest pharmaceutical companies in the US.

Chief of Staff to Chairman and CEO, Alex Gorsky. Responsible for leading the Strategic Planning Process for Johnson & Johnson, as well as the operations of the Executive Committee and Board of Directors. Led a cross-functional project team to separate the Consumer Health business of Johnson & Johnson into a separate, publicly traded company. Led a large team of internal and external partners in conducting full strategic assessment, performing detailed financial modeling and project planning, developing communications strategy and materials, and securing board approval.

Responsible for Tylenol, Children's Tylenol, Motrin, Children's Motrin, Imodium, Pepcid, Mylanta, Milicon and Rolaids brands